RudaCure, a company specializing in developing tratamientos for trastornos sensoriales, anunció que the compuesto líder desarrollo investigación for RCI002 — currently in desarrollo as a tratamiento del dolor crónico — ha sido seleccionada como a apoyoed proyecto under the Korea Drug Development Fund (KDDF) National New Drug Development Program.
The National New Drug Development Program is a cross-ministerial I+D initiative that apoyos the full lifecycle of desarrollo de nuevos fármacos based on an open innovación strategy involving empresas farmacéuticas, academia, investigación institutes, and hospitals, with the goal of strengthening the competitividad global of Korea's pharmaceutical and biotech industries and securing pharmaceutical sovereignty as an essential national health requirement.
A través de esto programa, RudaCure recibirá aproximadamente KRW 800 million in I+D financiamiento over two years and realizará investigación conjunta with the team of Professor Park Cheol-gyu at Gachon University College of Medicine, the lead institution.
The compuesto discovered by RudaCure selectively inhibits TRPV1 activity, and in prior investigación it demostró both TRPV1 inhibitory effects and pain reduction in dolor crónico animal models. Unlike existing TRPV1 antagonists, it does not cause abnormal fever, making it esperado to stand out as a highly effective analgesic with an excellent seguridad profile. Optimization investigación for comercialización will be carried out through this programa.
RudaCure El CEO Yongho Kim declaró: "Through investigación conjunta with Professor Park Cheol-gyu's team at Gachon University College of Medicine, who has extensive investigación experience in pain, we can break away from the traditionally low-probability desarrollo de fármacos approach and rapidly identify compuesto líders using computational science methods, which significantly shortens desarrollo de fármacos time — and this is very exciting."
RudaCure, 'TRPV1 Antagonist' Dolor Crónico — "Seleccionada for KDDF Project" (Biospectator)
http://www.biospectator.com/view/news_view.php?varAtcId=17129
Bio startup RudaCure seleccionada for National New Drug Development Program for tratamiento del dolor crónico (Medical Today)
https://mdtoday.co.kr/news/view/1065586503001454
Non-narcotic tratamiento del dolor crónico seleccionada for National New Drug Development Program (Medipharma)
http://www.medipharmnews.com/news/articleView.html?idxno=112361
Full-scale desarrollo of non-narcotic 'tratamiento del dolor crónico' begins (Herald Economy)
http://news.heraldcorp.com/view.php?ud=20220905000674
RudaCure "Non-narcotic 'tratamiento del dolor crónico' seleccionada for National New Drug Development Program proyecto" (Health Korea News)
https://www.hkn24.com/news/articleView.html?idxno=328843
RudaCure, non-narcotic 'tratamiento del dolor crónico' seleccionada for National New Drug Development Program proyecto (Medigate News)
http://www.medigatenews.com/news/3151924255
RudaCure, non-narcotic 'tratamiento del dolor crónico' seleccionada for National New Drug Development Program proyecto (Yakup Newspaper)
https://www.yakup.com/news/index.html?mode=view&cat=12&nid=273064
루다큐어 서울연구소